Recurrent and novel evolutionary pathways drive in vitro HIV-1 lenacapavir resistance with diverse phenotypic consequences

Link, J. O. et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature 584, 614–618 (2020).

Google Scholar 

Bester, S. M. et al. Structural and mechanistic bases for a potent HIV-1 capsid inhibitor. Science 370, 360–364 (2020).

Google Scholar 

Segal-Maurer, S. et al. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N. Engl. J. Med. 386, 1793–1803 (2022).

Google Scholar 

Bekker, L. G. et al. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N. Engl. J. Med. 391, 1179–1192 (2024).

Google Scholar 

Kelley, C. F. et al. Twice-yearly lenacapavir for HIV prevention in men and…